ATNX - Athenex: Is This Stock A Buy Sell Or Hold? It's A Hold.
- Athenex, Inc. is a biopharmaceutical company developing and commercializing next-generation drugs for treating various cancers.
- Athenex's pipeline consists of four therapeutic programs, Orascovery (P-glycoprotein pump inhibitor), Src Kinase Inhibition, Cell Therapy, and Arginine Deprivation Therapy.
- Athenex's lead therapeutic is Klisyri (tirbanibulin) launched in the US in Feb 2021 with an EU launch expected in 2H’21 under a partnership with Almirall.
- Athenex received a CRL from the FDA in Feb'21 for Oral paclitaxel + encequidar's and now Athenex is planning a new study design expected to be presented in 4Q 2021.
- In summary, the author projects Athenex, Inc. as a "hold".
For further details see:
Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.